Effect of L-Acetylcarnitine on body composition in HIV-related lipodystrophy

S. Benedini, G. Perseghin, I. Terruzzi, P. Scifo, P. L. Invernizzi, A. Del Maschio, A. Lazzarin, L. Luzi

Research output: Contribution to journalArticlepeer-review


This study examined the impact of L-acetylcarnitine treatment on metabolic parameters and body composition in patients with lipodystrophy syndrome secondary to antiretroviral treatment in human immunodeficiency virus (HIV) infection. A total of 9 HIV-1 infected patients with lipodystrophy syndrome (4F/5M, age 41±5 years, HIV duration 8±2 years, BMI 23.7±3.4kg/m2, on protease inhibitors and nucleoside analogue Reverse Transcriptase inhibitors) were evaluated before and after 8 months of therapy with L-acetylcarnitine (2g/die) and 9 matched healthy subjects served as control subjects. In all patients fasting plasma glucose, insulin concentrations (for evaluation of surrogate indexes of insulin sensitivity), lipid profile, lipid oxidation (by indirect calorimetry), body composition (by DEXA), and intramyocellular triglyceride (IMCL) content of the calf muscles (by 1H NMR spectroscopy) were assessed. After this therapy, in HIV-1 patients, the IMCL content of the soleus had significantly decreased (p=0.03). Plasma FFAs (0.79±0.31 to 0.64±0.25; p

Original languageEnglish
Pages (from-to)840-845
Number of pages6
JournalHormone and Metabolic Research
Issue number11
Publication statusPublished - Nov 2009


  • Energy metabolism
  • Human immunodeficiency virus
  • Insulin sensitivity
  • Nmr spectroscopy

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Effect of L-Acetylcarnitine on body composition in HIV-related lipodystrophy'. Together they form a unique fingerprint.

Cite this